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Correlation between objective measures of airway
calibre and clinical symptoms in asthma:
a systematic review of clinical studies
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Clinical symptoms are often used as a measure in asthma management, but a variety of symptoms and scales are
available. The objectives of this systematic review were as follows:
(a) to present correlations between symptoms and measures of airway calibre; (b) to present the scoring systems/
scales used in the publications.
In the review, more than 10 000 publications were found under the key words: asthma and symptom(s). Twenty-
one remained when FEV1/PEF, scale/score and correlation were added as key words.
In summary, no standardized method exists for measuring asthma symptoms with respect to severity. This is the
case for both the symptoms and the scales. There are two recently-developed asthma-control scales available (one
of which has not yet been published and is not included in the review).
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Asthma is a chronic disease which aects the daily lives of
many patients. It is characterized by coughing, wheezing,
chest tightness and dicult breathing that are usually
reversible. Intermittent exacerbations occur in which the
severity of symptoms increases and the response to therapy
may be reduced. The goals of asthma therapy are to
improve the patient’s quality of life by achieving and
maintaining control of symptoms, preventing exacerba-
tions, attaining normal lung function and maintaining
normal activity levels.
Objective measurements have been, and still are,
important in the evaluation of the status of patients with
asthma. Measurements of airway function, such as forced
expiratory volume in 1 sec (FEV1) and peak expiratory flow
(PEF), were the first parameters to be used for assessing
disease severity. Spirometry test and measurements of PEF
are recommended to be performed in a standardized way
which gives confidence to these measurements. The
recommended methods have been developed and published
by both European and North American societies. Despite
recommendations for performance, calibration of instru-
ments and patient education are still points to consider.
However, these measurements have been, and are, invalu-Received October 1999 and accepted in revised form 25 February
2000.
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airway function. Still, it has proved a little more dicult to
translate such measurements into an understanding of
whether or not the improvement is clinically important.
The objective measurements such as FEV1 and PEF do
not always reflect all the disease processes, such as
hyperinflation and airway plugging, that occur in asthma.
Evidence from clinical studies suggests that lung function
measurements do not always follow other markers of
disease activity. In a study in mild asthmatic patients
treated with budesonide or placebo for 1 year, asthma
symptoms improved in steroid-treated patients but not in
those receiving placebo. Despite these improvements, there
was no change in FEV1 (1).
Moreover, in patients with mild asthma there are no
measurements sensitive enough to evaluate the treatment,
even though patients may experience a reduction in airway
symptoms.
Clinical symptoms of asthma are often used in clinical
studies but not collected in a standardized way. The
relationship between the perception of asthma symptoms
and lung function measurements in asthmatic patients is
poorly understood (2). It is also important to distinguish
between asthma severity and asthma control. Asthma
severity may be defined as an estimate of the severity of
the underlying disease process, whereas asthma control is
an estimate of the ecacy of treatment (3). The majority of
studies in this review used dierent symptom scales in order
to measure severity. In one publication an asthma control
scale was used.# 2000 HARCOURT PUBLISHERS LTD
736 E. STA˚HLOver the last 25 years much research has been conducted
concerning the development and validation of a question-
naire that would quantify the impact of disease on daily life
and well-being from the patient’s point of view. In recent
years a number of both generic and disease-specific quality
of life questionnaires have been developed. Problems have
been experienced in producing a questionnaire which is
sensitive enough to detect any change, as many patients
with mild asthma do not undergo any measurable
deterioration in their quality of life, thereby making it
impossible to show any improvement (4).
Other possible limitations with questionnaires may be the
linguistic validation. Recommendations of how a proper
translation, which also includes a cultural adaptation,
should be performed are published (3,4). However, these
recommendations are focused on quality of life question-
naires, and symptom questionnaires are often not con-
sidered as having the same degree of importance.
‘Symptom-free days’ is an outcome variable recom-
mended in the guidelines for use in economic evaluations
of asthma (5). In a publication by P.W. Jones, an attempt
was made to identify all possible measurements of disease
severity in mild asthma, one of which is symptom-free days
(6). However, it is relatively insensitive because no
consideration has been given to the severity of symptoms.
OBJECTIVES
This systematic review has the following objectives: (a) to
present correlations between symptoms and measures of
airway calibre (dierent scoring systems for symptoms will
also be discussed); and (b) to present the scoring systems/
scales used in the publications.
Methods
In a literature search in MEDLINE, EMBASE and Current
Contents for publications dating from 1966 to March 1998,
10 221 references were found under the key words asthma
and symptom(s). The most commonly mentioned symp-
toms were wheeze and cough, followed by dyspnoea. The
figures below show the number found in each of the
databases.
In a review covering all publication years, wheeze was
mentioned in 1534 papers in MEDLINE, 602 in EMBASE
and 251 in Current Contents. Cough was found in 1492
articles in MEDLINE, 678 articles in EMBASE and 195 in
Current Contents. For dyspnoea the figures were 1060 in
MEDLINE, 411 in EMBASE and 99 in Current Contents.
Other frequently mentioned symptoms were sputum, short-
ness of breath, chest tightness and phlegm. In this review,
no consideration has been given to the frequency or
duration of the symptoms. Publications dealing with
Quality of Life questionnaires including symptoms have
been excluded from the present review.
In this review, the key words ‘asthma’ and ‘symptom’
have been combined. Additional key words are: forced
expiratory volume in 1 sec (or FEV1); peak expiratory flow
(or PEF); score or scale and correlate.Twenty-one publications were found. In the section
below, the papers that included correlations between
symptom scales and FEV1/PEF will be presented, and the
dierent scales and scores will be discussed.
Results
CORRELATIONS
In 20 of the 21 publications, a test for correlation between
symptoms and FEV1/PEF was performed. The remaining
paper was a review article. Details of all studies are
presented in Tables 1 and 2. In 15 studies there was little or
no correlation between symptoms and spirometry tests, but
in the remaining five studies statistically significant correla-
tions were found between the subjective and objective
measurements. However, in a few studies the correlation
values were mixed, i.e. statistically significant correlations
were found in a number of comparisons, whilst the
remaining correlations were not statistically significant.
Eight studies were performed in children and/or adolescents
with asthma, and the other 13 in adult asthmatic patients.
In the following five studies (nos. 3, 14, 15, 18 and 19 in
Tables 1 and 2) a statistically significant correlation was
found between airway calibre and symptoms.
In one paper, number 3 by Blanc et al., published in 1993,
the severity of asthma score based on clinical variables was
shown to correlate with work disability, r= 70?6,
P50?001 (7). However, this study had only one question
on respiratory symptoms. The remaining questions con-
cerned steroids and rescue medication etc., a total of 12
additional questions with yes/no answers.
In the second study (No. 14 in Tables 1 and 2), per-
formed by Morris et al. and published in 1996, the severity
module from the Monash Respiratory Questionnaire was
used (8). This questionnaire was developed by one of the
authors and includes frequency of wheezing, nocturnal
attacks, asthma attacks, nocturnal wheeze, exercise-induced
asthma and dyspnoea. In addition, there are questions on
history of emergency room visits, hospitalizations and use
of oral steroids. The asthma severity scores correlated with
use of rescue medication and daily dose of inhaled steroids,
but not with FEV1 or forced vital capacity (FVC). The
severity module of the Monash Respiratory Questionnaire
was shown to be a valid and reliable instrument for
measurement of the severity of asthma.
The third of these studies (No. 15 in Tables 1 and 2) was
published in 1985 by Pauli et al. and shows an individual
correlation between objective and subjective measurements
(9). There were four parameters in the symptom scoring,
night-time and daytime dyspnoea, breathlessness and cough.
The scores ranged from 0 (no symptoms) to 3 (maximum
symptom score). The authors found a global correlation
between symptoms and PEF that was statistically significant
in 10 out of 13 patients (P=0?01 in eight cases and P=0?05
in two cases). When use of medication (bronchodilators and
corticosteroids) was compared with symptoms, the correla-
tion was statistically significant in only eight of the 13
patients. However, incomplete diary cards revealed
TABLE 1. Characteristics of patients and design from publications
Author (publ. year) No. of
patients
Age range
mean or (years)
Study design Study duration
1 Apter A.J. (1994) 13 mean 43.5 PEF, symptoms at home 9 weeks
2 Bailey W.C. (1992) 199 15%530 years,
10%470 years
FEV1 1 day
3 Blanc P.D. et al. (1993) 56 18–55 FEV1 1 day+1 day 2 yrs later
4 Boulet L.P. (1991) 26 mean 43.2 PEF, symptoms at home 4 weeks (after acute
exacerbation)
5 Carswell F. et al. (1990) 86 5–15 (mean 11.2) PEF, symptoms at home 1 week
6 Enright P.L. et al. (1994) Review
article
— — —
7 Foo A.L. et al. (1996) 100 6–19 PEF, symptoms at home,
FEV1 at visit
2 weeks
8 Fritz G.K. et al. (1996) 5 10–15 PEF, FEV1 symptoms at visit 1 day
9 Gern J.E. et al. (1994) 74 5–12 PEF, symptoms at home 6 months
10 Hewson P.H. et al. (1996) 27 10–15 19 patients: PEF, symptoms
at home
All: FEV1
1 day
11 Linna O.V.E. (1991) 31 9–15 (mean 12.3) PEF, symptoms at home 3 weeks
12 Linna O. (1996) 65 6–16 (mean 11.4) PEF, symptoms at home 3 weeks
13 Molema J. et al. (1989) 14 16–37 (mean 27) PEF, symptoms at home 6 weeks
14 Morris N.V. et al. (1996) 72 6–79 PEF at home
Monash Respiratory
Questionnaire
2 weeks
15 Pauli G. et al. (1995) 13 19–40 PEF, symptoms at home 16 weeks
16 Peier C. et al. (1992) 33 17–72 (mean 50) PEF, symptoms at home 10 days
17 Quirk P.H. et al. (1990) 40 18–72 (mean 37) FEV1, 29 symptom questions 1 day
18 Reddel H.K. et al. (1995) 46 21–71 (mean 36.1) PEF, symptoms at home 3 months
19 Santanello N.C. et al. (1997) A: 239
B: 107
A: mean 35
18–65
B: mean 44
PEF, symptoms at home A: 6 weeks
B: 4 weeks
20 Teeter J.G. et al. (1998) 28 12–16 (mean 14) PEF, symptoms at home 12 weeks
21 Uwyed K. et al. (1996) 67 mean 32.7 PEF, symptoms at home,
FEV1
7.9 weeks
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many symptoms recorded). The authors concluded that a
significant correlation between symptom score and PEF
may be obtained if patients are given precise instructions
about limiting the use of bronchodilator therapy.
In the fourth study (No. 18) published by Reddel et al. in
1995 (10), an index of PEF was compared with symptoms
as well as with 2-agonist use and PD20. Forty-six adult
patients at the clinic were asked to rate their symptoms
using a frequency score from 0 to 4 (0=no symptoms for 3
months, 4=waking once or more a week because of
asthma). The correlation between PEF and symptoms
(r=70?54) was weaker than between PEF and PD20
(r=70?21), but both were statistically significant.
In the fifth study (No. 19) published in 1997 by
Santanello et al., two dierent scales for measuring asthma
symptoms were compared with PEF (11). This is the only
study that evaluates symptom scores with respect to asthmacontrol. The daytime asthma symptom scale used a range of
response categories for each question from 0 to 6,
indicating the least to the most asthma symptomatology.
The nocturnal diary scale used response categories ranging
from 0 (indicating no awakenings with asthma symptoms)
to 3 (indicating being awake all night due to asthma
symptoms). Daily daytime scale scores were computed as
the average of four questions: (a) frequency of general
asthma symptoms; (b) inconvenience of asthma symptoms;
(c) frequency of limitation during activities and (d) how
often asthma symptoms limited ability to perform usual
activities.
Weekly average scores for the nocturnal diary scale were
computed in the same manner. The internal consistency,
reliability, validity and responsiveness of both scales were
assessed in 346 adult asthma patients in two placebo-
controlled studies of an investigational asthma therapy, a
leukotriene inhibitor.
TABLE 2. Symptoms and correlations vs. airway calibre
Reference Symptoms Correlations
Symptoms vs. airway calibre
Significance
Score Items
1 Apter A.J. (1994) 1–4 cough, wheeze, chest tightness,
dyspnoea
r=70?59–0?27 (range all pa-
tients)
P=0?0001–0?12
N.S. in 5/13 patients
2 Bailey W.C. (1992) Yes–No
slight-mod-severe
1–5
resp. symptoms
bother scale
r= 70?21 (resp. symptoms)
r=70?10 (bother scale)
P50?01
N.S.
3 Blanc P.D. et al. (1993) 0–28 history of hosp, frequency of
symptoms, past and current
use of steorids
r=70?6 P5 0?0001
4 Boulet L.P. (1991) 0–10 dyspnoea, cough, chest
tightness, phlegm
8 patients r= 0?685–0?842
18 patients no correlations shown
P5 0?001–0?004
5 Carswell F. et al.(1990) 0–13 day, night r=70?20
r=70?33
N.S.
P= 0?05
6 Enright P.L. et al. (1994) review article — — —
7 Foo A.L. et al. (1991) 0–4
0–2
night time symptoms
morning tightness
r=0?16 (vs. FEV1 )
r= 0?3 (vs. PEF)
N.S.
N.S.
8 Fritz G.K. et al. (1996) VAS r=70?03–0?50 P5 0?05 in 2/5 patients
9 Gern J.E. et al. (1994) 0–3 wheeze, cough activities r= 0?22 P=0?058
10 Hewson P.H. et al. (1996) 0–5 day, night 11 patients r=0?3 (vs. FEV1 ) CI: 0?16 to 0?47
11 Linna O.V.E. (1991) 0–3 day, night r= 0?32 N.S.
12 Linna O. (1996) 0–3 day, night r=70?25 P= 0?06
13 Molema J. et al. (1989) 0–3 dyspnoea, wheeze, cough r=0?27
r=0?14
N.S.
N.S.
14 Morris N.V. et al. (1996) 0–4
Yes–No
Monash Respiratory
Questionnaire (14 questions)
r=0?34 (vs. PEF variability) CI: 0?09–0?53
15 Pauli G. et al. (1995) 0–3 breathlessness, cough r= 0?3905 P=0?001
16 Peier C. et al. (1992) VAS, 0–100 mm dyspnoea r= 0?04 (carbachol group n=14)
r=0?14 (salbutamol group n=19)
NS
NS
17 Quirk P.H. et al. (1990) VAS, 0–100 mm 29 symptom items 1 symptom item correlated with
FEV1
P=0?01
18 Reddel H.K. et al. (1995) 0–4, frequency one symptom item r=70?54 P5 0?0001
19 Santanello N.C. et al. (1997) 0–6 daytime diary scale
nocturnal diary scale
Day: A: r=70?49 Night: A:
r=70?32
Day: B: r=70?38 Night: B:
r=70?51
(70?58 to 70?38) (70?53 to 70?20)
(70?43 to 70?20) (70?64 to 70?35)
20 Teeter J.G. et al. 0–12 daytime cough or wheeze,
notification of activities,
nocturnal cough or wheeze
patient 1 r=0?78
patient 2 r= 0?02
P5 0?0001
P=0?88
21 Uwyed K. et al. (1996) 0–4 cough, dyspnoea, wheeze,
notification of activities,
nocturnal awakening
PEF: r=0?384 (n=58)
FEV1: r=0?143 (n=70)
P=0?0029
P=0?263
Statistical significance listed as P-values or CI. All data from publications.
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consistency (0.90–0.92), and the daytime and nocturnal
symptom scales showed sucient test–retest reliability
(0.69–0.87). Construct validity was demonstrated by gen-
erally moderate to strong correlations between changes in
the diary scales and changes in other measurements of
asthma, such as FEV1/PEF and number of rescue inhala-
tions. Both scales also demonstrated significant responsive-
ness to change in asthma due to therapy in one of the
clinical studies. The authors concluded that both the
daytime and the nocturnal asthma symptom diary scales
show measurement characteristics appropriate for use as
asthma measures in clinical studies.
In addition, an asthma outcome study (No. 6) was
published by Enright et al. in 1994 (12). This is a review
article showing that all lung function tests were significantly
correlated with each other and with symptom scores.
However, no correlation tests were presented. Since there
is no ‘gold standard’ with which to measure asthma
severity, all of these tests contribute additional unique
information when measuring asthma outcome.
Fifteen of the studies found low or no correlation
between symptoms and airway calibre.
Study No. 1 (Tables 1 and 2) was published by Apter
et al. in 1994 (13). Three clinical measures (symptom scores,
morning PEF and number of rescue inhalations) were
compared in 13 patients. It was concluded that the
commonly used measures described above may not be
interchangeable for describing the clinical course of asthma.
It was also apparent that patients whose use of 2-agonist is
determined by symptoms tend to be more compliant.
In the study by Bailey et al., published in 1992 (No. 2 in
Tables 1 and 2), it was concluded that asthma severity
appears to be multi-dimensional rather than uni-dimen-
sional, and includes at least three components (14). They
suggested the use of the ‘Physician Rating Scale’, as it
provides a useful summary of the severity of the asthma.
The three dimensions that were proposed were: (a)
symptom intensity, (b) airflow impairment and (c) manage-
ment intensity.
In the next study by Boulet et al., published in 1991 (No.
4), recovery from asthma symptoms and lung function were
compared in 26 patients after an acute exacerbation of
asthma (15). Using a scale of 0–10 (0=no symptom,
10=maximum), the symptoms asked for were cough,
dyspnoea, chest tightness and phlegm production. As
expected, there was great variability in symptom scores. It
was observed that patients with a shorter duration of
asthma could not only perceive more symptoms, but could
also discriminate their asthma symptoms better.
Number 5 (Tables 1 and 2) was published by Carswell
et al. in 1990 (16). This is a study performed in 86 children
with a mean age of 11?2 years in which the relationship
between the physical severity of asthma and the family’s
knowledge and feelings about the disease was measured.
The symptoms were recorded every day and were scored
from 0–13 (maximum). The mean PEF recorded prospec-
tively for 1 week correlated with the symptom score. Increa-
sed nocturnal symptoms correlated weakly with lower mean
overnight PEF (not significant), and higher daily symptomscores correlated with lower mean daily PEF (statistically
significant). It was concluded that more information is
needed in order to increase families’ knowledge of asthma.
In another study in children by Foo and Sly, published in
1991 (No. 7), no correlation was found between symptom
scores (scored from 0–4, 0=no symptoms) and FEV1 or
PEF (17). Their study showed that 35% of the children had
abnormal lung function despite the fact that they had
recorded very low symptom scores. The authors suggested
that PEF-meters at home can provide a valuable aid for
self-management.
In a study by Fritz et al. in 1996 (No. 8), symptom
perception in childhood asthma was evaluated (18). These
authors suggested an arithmetic calculation including a
symptom scale (visual analogue scale, 0–100mm), FEV1
and PEF. They let the children guess their FEV1 and their
PEF and compared these values with the actual values. No
correlation was shown as only five children participated,
and they showed great variation. The authors suggested
further research.
Gern et al. published a study (No. 9, 1994) of 74 children
in which PEF variation and symptom scores were
compared (19). The symptom scores included wheezing or
coughing and daily activities, and were scored from 0–3
(0=none or no limitation, 3=persistent symptoms or daily
routine modified). The change in symptom scores did not
follow the change in diurnal variation of PEF, and no
correlation was found between them. The usefulness of the
diurnal variation was discussed, and the conclusion was
that it is an imprecise indicator of the severity of asthma.
The next study, by Hewson et al. (No. 10, 1996),
compared lung function tests and asthma symptoms in 27
adolescents (20). Asthma symptoms were scored from 0–5
for daytime and night-time as follows: 0=no symptoms
during the previous 2 weeks, 5=symptoms so severe as to
aect normal activities or sleep. Most of the patients with
low PEF values of 25–75% predicted who did not correlate
with symptoms had values below 55% of predicted value.
The conclusion was that measurement of lung function
should be part of the clinical assessment.
The following two studies were published by Linna, in
1993 (No. 11) and in 1996 (No. 12) (21,22). Both studies
were performed in children, and the conclusion was that
symptom scores in a diary are a poor basis for the
assessment of childhood asthma. The value of monitoring
PEF at home was discussed, and it was concluded that this
is of limited value when assessing the degree of severity of
asthma.
In a study by Molema et al., published in 1989 (No. 13),
asthma symptoms were obtained and compared with other
objective measures such as FEV1, 2-agonist use and PC20
(23). The symptoms asked for were daytime dyspnoea,
wheeze and cough, as well as nocturnal dyspnoea
and wheeze, and the scores were from 0–3 (0=no
symptoms, 3=severe symptoms). Fourteen adult patients
with exercise-induced asthma participated. No correlation
was found between the symptom scores and any of the
other measurements. The conclusion was that symptom
scores are of little value in assessing the severity of the
disease.
740 E. STA˚HLIn a study by Peier et al. from 1992 (No. 16), the
relationship between spontaneous dyspnoea and the lability
of airway obstruction in asthma was investigated (24). The
correlation coecient r between dyspnoea scores (VAS
scores, 0–100mm) and PEF (r DSc-PEF) was determined.
There was a large inter-subject dierence in the character-
istics of dyspnoea.
In the study by Quirk and Jones, published in 1990 (No.
17), a visual analogue scale was used (25). Twenty-nine
items referred to severity and frequency of symptoms such
as frequency of cough, wheeze, shortness of breath and
sputum production. There was no significant association in
a regression of FEV1 against the mean score for each of the
40 patients. It appeared that symptoms alone contributed
relatively little directly to the overall level of the disease
experienced by patients.
Another study showing no correlation between lung
function and symptoms was published by Teeter and
Bleeker in 1997 (No. 20) (26). In that study six symptoms,
including cough, dyspnoea, wheeze, chest tightness, sputum
production and nocturnal awakenings, were rated by 67
patients on a scale from 0 (none) to 4 (constant). Asthma
symptoms did not correlate with FEV1 or PEF. The
authors noted that following treatment, subjective improve-
ment in asthma symptoms could occur without any
improvement in measurements of airway obstruction.
In the last study by Uwyyed et al. from 1996 (No. 21),
children completed a diary including the following symp-
toms: nocturnal cough or wheeze, daytime cough or
wheeze, and limitation of normal activities, with a
maximum possible daily score of 12 (27). Low correlations
were found between the daily symptom scores and the lung
function measurements. There was a higher correlation
between PEF and symptoms in children with more severe
disease.
Taken together these studies demonstrate that there are
only weak correlations between objective measures of
airway calibre, such as FEV1/PEF, and subjective measures
such as symptoms.
SYMPTOM SCALES
Great variation was found in the scales/scoring systems
used in the studies reported here. Scores of 0–3, where 0
means no symptoms and 3 means maximum symptoms,
were used in four studies. In some studies the symptoms
were divided into cough, breathlessness and wheeze,
whereas in other studies daytime and night-time symptoms
were recorded. In a few studies both combinations were
used. Scales using ratings of 0–4, 0–5, 0–10 and 0–12 were
also used, and with great variation. In three of the studies a
visual analogue scale was used. As mentioned previously,
no two studies used the same scale, which is a drawback
since no comparisons can be made between the results.
The study by Santanello et al. demonstrated an attempt
to standardize the scale by comparing dierent items and
analysing them by using a psychometric test. It must be
mentioned, however, that this scale is not a severity scale
but an asthma control scale. This is the only study in thereview that presented an asthma control scale; all other
publications included dierent questions or scales concern-
ing symptom severity. One of these is the severity module in
the Monash Respiratory Questionnaire, which seems well
validated and constitutes a good attempt to standardize the
measurement of the severity of asthma.
Discussion
It is obvious from this review that objective measurements
such as FEV1/PEF and subjective asthma symptom scales
give dierent information about the status of a patient’s
asthma. Many of the authors concluded that it is of
importance to measure FEV1/PEF in order to control the
severity of asthma, especially in children who may not be
aware of any deterioration in their asthma. However, it
seems reasonable that objective measurements as well as the
subjective ones are important to have the full picture of a
patient and his/her disease. It may be discussed if a patient
should measure PEF or fill in a symptom questionnaire
every morning. In clinical studies it is often the case but not
in real life. When looking at the correlations between PEF
and symptoms, these were not higher when comparing
FEV1 with symptoms (Table 2). It must be highlighted that
the variety of studies in terms of design, patient number and
study duration is an advantage in drawing any conclusions.
Data on confidence intervals are not presented in the
majority of studies which also adds weaknesses to the review.
In mild asthma with almost no decrease in FEV1 or PEF,
there is a need for a sensitive subjective measurement of the
symptoms that exist in this patient group. When comparing
dierent treatments in clinical studies, there is a need for a
standardized asthma control scale. The scale presented by
Santanello et al. constitutes a good attempt to standardize a
scale. A similar asthma control scale was recently developed
by Juniper et al. (28). This questionnaire was tested in a 9-
week observation study of 50 patients with asthma. The
reliability of the questionnaire was high (ICC=0?90) and
the responsiveness to change was significant (P50?0001).
However, further evaluation of the questionnaire is
required, as the number of patients was relatively small
and the group may have been homogenous.
To summarize, 21 studies were identified in which
correlations were sought between objective measures such
as FEV1/PEF and subjective measures such as asthma
symptoms. The majority of the studies found no significant
correlation. Great variation exists in the way asthma
symptoms are evaluated, with each study employing a
dierent set of symptoms and scales. A few attempts have
been made to standardize the recording of symptoms, but
at present no asthma symptom scale can be considered ideal
or reliable. Further work is needed, especially in the
development of scales applicable to patients with very mild
asthma in whom lung function measurements are typically
normal. It is also important to highlight the linguistic
validation of symptom scales. The recommendations given
for quality of life questionnaires can be used as guidelines
for symptom scales with some modifications. The conclu-
sion is that for the time being, objective measurements still
CORRELATION BETWEEN OBJECTIVE MEASURES OF AIRWAY CALIBRE AND CLINICAL SYMPTOMS IN ASTHMA 741provide the best information about the severity of a
patient’s asthma status.
Further research is needed for: (a) development of
standardized and validated symptom scoring systems; (b)
development of validated symptom scores/scales for mild
asthma; (c) exploration of the relationship between
symptom perception and compliance with therapy; and
(d) understanding the physiological basis of asthma
symptoms.
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